Dyne Therapeutics, Inc. - Common Stock (DYN)

Investors were haunted by the specter of share dilution.

Stocks largely stayed in a holding pattern awaiting tomorrow's pronouncement from the Federal Reserve.

New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly positive news. Despite announcing highly encouraging clinical trial results for its lead Duchenne muscular dystrophy (DMD) candidate, DYNE-251, the company's

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

The company has solid potential with its development of drugs targeting muscle disorders.

Biotechs like it are clearly valuable to strategic acquirers.

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes.